A Phase 3 interventional study of Tocilizumab and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 32 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-02.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 38th largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 80th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 9 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 68th largest by enrollment of the 141 interventional ones that give a count, is one of 10 that started in 2014, is one of 85 in phase 3, and was the 178th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This two part, multi-center, open-label, single-arm study will evaluate the efficacy and safety of tocilizumab as a monotherapy or in combination with methotrexate or other conventional synthetic disease modifying antirheumatic drugs (csDMARDs) in participants with moderate to severe active rheumatoid arthritis who have an inadequate response or are intolerant to non-biologic csDMARDs and/or biologic therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection once a week administered as monotherapy or in combination with methotrexate or other csDMARDs (at investigator's discretion) for 24 weeks. Participants who complete the core study period will be allowed to enter a long-term-extension (LTE) period to continue study treatment for up to a maximum of another 52 weeks or until the commercial availability of SC tocilizumab, whichever occurs first.
Drug: Tocilizumab · Drug: Methotrexate · Drug: csDMARDs
Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
Also known as: RoActemra, RO4877533
Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
Change From Baseline in Disease Activity Score Based on 28-joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24
The DAS28-ESR was derived from assessments of erythrocyte sedimentation rate (ESR), tender joint count (TJC), swollen joint count (SJC), and Patient Global Assessment of disease activity (PGA) according to 100-millimeter (mm) Visual Analog Scale (VAS). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in millimeters per hour (mm/h). DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to Week 24 was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Week 24
Change From Baseline in DAS28-ESR at Weeks 2, 4, 8, 12, 16, 20, and 24
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With DAS28-ESR Low Disease Activity (LDA) and Remission at Week 24
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score less than or equal to (\</=) 3.2 indicates LDA, DAS28-ESR score greater than (\>) 3.2 indicates moderate to high disease activity, and DAS28-ESR less than (\<) 2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 is reported. 95 percent (%) confidence interval (CI) was determined using Clopper-Pearson method.
Time frame: Week 24
Change From Baseline in DAS28-ESR at Week 24 and at Last Assessment
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-millimeter (mm) VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Week 24, last assessment (up to Week 76)
Percentage of Participants With DAS28-ESR LDA and Remission at Week 24 and at Last Assessment
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score \</=3.2 indicates LDA, DAS28-ESR score \>3.2 indicates moderate to high disease activity, and DAS28-ESR \<2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 and at last assessment is reported.
Time frame: Week 24, last assessment (up to Week 76)
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response at Week 24
The ACR 20, 50, and 70 responses at any time was defined as greater than or equal to (\>/=) 20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via a Health Assessment Questionnaire-Disability Index (HAQ-DI), and 5) Acute phase reactant (ESR in mm/h or C-Reactive Protein \[CRP\] in milligrams per liter \[mg/L\]). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.
Time frame: Baseline, Week 24
Percentage of Participants Achieving ACR20, ACR50, and ACR70 Response at Week 24 and at Last Assessment
The ACR 20, 50, and 70 responses at any time is defined as \>/=20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/L). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 and at last assessment is reported.
Time frame: Baseline, Week 24, last assessment (up to Week 76)
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28-ESR at Week 24
The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline \>1.2 with DAS28-ESR score \</=3.2; Moderate Response: change from baseline \>1.2 with DAS28-ESR score \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28-ESR score \</=5.1; No Response: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28-ESR score \>5.1. Percentage of participants with EULAR responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.
Time frame: Baseline, Week 24
Percentage of Participants With EULAR Response Based on DAS28-ESR at Week 24 and at Last Assessment
The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline \>1.2 with DAS28-ESR score \</=3.2; Moderate Response: change from baseline \>1.2 with DAS28-ESR score \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28-ESR score \</=5.1; No Response: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28-ESR score \>5.1. Percentage of participants with EULAR responses at Week 24 and at last assessment is reported.
Time frame: Baseline, Week 24, last assessment (up to Week 76)
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, and 24
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg per deciliter (dL). Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With SDAI LDA and Remission at Week 24
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.
Time frame: Week 24
Change From Baseline in SDAI at Week 24 and at Last Assessment
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Week 24, last assessment (up to Week 76)
Percentage of Participants With SDAI LDA and Remission at Week 24 and at Last Assessment
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 and at last assessment is reported.
Time frame: Week 24, last assessment (up to Week 76)
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 12, 16, 20, and 24
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Percentage of Participants With CDAI LDA and Remission at Week 24
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.
Time frame: Week 24
Change From Baseline in CDAI at Week 24 and at Last Assessment
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Week 24, last assessment (up to Week 76)
Percentage of Participants With CDAI LDA and Remission at Week 24 and at Last Assessment
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 and at last assessment is reported.
Time frame: Week 24, last assessment (up to Week 76)
Change From Baseline in SJC at Weeks 2, 4, 8, 12, 16, 20, and 24
A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in SJC at Week 24 and at Last Assessment
A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Week 24, last assessment (up to Week 76)
Change From Baseline in TJC at Weeks 2, 4, 8, 12, 16, 20, and 24
A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in TJC at Week 24 and at Last Assessment
A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity.
Time frame: Baseline, Week 24, last assessment (up to Week 76)
Change From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, 8, 12, 16, 20, and 24
Physician-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in physician-assessed disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Change From Baseline in PGA at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Participant-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed disease activity.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Change From Baseline in Pain VAS Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Participant-assessed pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of pain (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed pain.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated questions), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). The changes from Baseline to any time point were averaged among all participants, where negative changes indicated an increase in fatigue.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Percentage of Participants With Health Assessment Questionnaire-Disability Index (HAQ-DI) Remission at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI remission (HAQ-DI score \<0.5) at each time point is reported.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Percentage of Participants With HAQ-DI Clinically Meaningful Improvement at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI clinically meaningful improvement (reduction in HAQ-DI score from baseline \>/=0.22) at each time point is reported.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Treatment Compliance From Baseline up to Week 24
Treatment compliance from Baseline up to Week 24 was assessed using following formula: (number of actual injection received / number of theoretical injection which should be received at week 24) \* 100.
Time frame: Baseline up to Week 24
Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Score at Weeks 12, 24, 28, 40, 52, and 64
RAID assessed the impact of rheumatoid arthritis on participant's quality of life. It comprised 7 domains: pain, function, fatigue, physical and psychological well-being, sleep disturbance and coping. Each domain was a single question scored from 0 (best) to 10 (worst) on a continuous numerical rating scale (NRS). Each domain also had a specific weight assigned by a participant survey and RAID total score ranged from 0 (best) to 10 (worst). If only 1 domain was missing it was replaced by the mean of the others; otherwise, RAID score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life.
Time frame: Baseline, Weeks 12, 24, 28, 40, 52, and 64
Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID-3) at Weeks 2, 4, 12, 24, 28, 40, 52, and 64
RAPID-3 is a combined index derived from the Multidimensional Health Assessment Questionnaire that includes physical function score, pain VAS, and PGA VAS. The total RAPID-3 score ranges from 0 to 10 where higher scores represent worse outcomes. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
Time frame: Baseline, Weeks 2, 4, 12, 24, 28, 40, 52, and 64
Number of Participants With Patient Acceptable Symptom State (PASS) Score
Participants were asked: "If you were to remain in the same condition for the next few months as you have been over the last 8 days, would this be 1) acceptable, 2) Inacceptable?" The number of participants who responded "acceptable" or "Inacceptable" at each time point is presented.
Time frame: Baseline, Weeks 24, 52, and last assessment (up to Week 76)
Change From Baseline in Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) Total Score at Weeks 24 and 52
BRAF-MDQ assessed the overall experience and impact of disease related fatigue, using four dimensions (physical fatigue \[4 items\], living with fatigue \[7 items\], cognitive fatigue \[5 items\], and emotional fatigue \[4 items\]). A total fatigue score (range 0 to 70) was obtained by summing the 20 item scores ranging from 0 to 3, except for item 1 (0-10), item 2 (0-7) and item 3 (0-2). Higher scores reflect greater fatigue. If only 1 domain was missing it was replaced by the mean of the others; otherwise, the total score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in Bristol Rheumatoid Arthritis Fatigue (BRAF)-NRS Score at Weeks 24 and 52
BRAF-NRS are 3 standardized NRS (range = 0-10) for disease related fatigue domains (severity of fatigue, fatigue effect, and coping with fatigue). Higher values reflect greater problems for severity/level fatigue and effect fatigue NRS, but lower scores reflect greater problems for copped fatigue NRS.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in Medical Outcome Study (MOS) Sleep Questionnaire Score at Weeks 12, 24, 28, 40, 52, and 64
MOS sleep scale comprised of 6-item with each item score ranged from 0 to 100. The total score was the average of scores sum (range 0-100), with highest values reflecting biggest participant's sleeping problems. If more than 3 items were missing the index was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
Time frame: Baseline, Weeks 12, 24, 28, 40, 52, and 64
Change From Baseline in Fluctuations of Disease Activity in Rheumatoid Arthritis (FLARE) Questionnaire Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 40, 52, and 64
FLARE is a 13-item questionnaire assessed disease flares between two medical consultations. Each item score ranged from 0 (completely untrue) to 10 (absolutely true) on a 6-step scale. The FLARE questionnaire global score (range = 0-10) is a mean score of 11 of the 13 items \[items 6 ('doses of pain killers or anti-inflammatory medication') and 13 ('need for help') not taken into account\], with the highest score corresponding to the highest disease activity. The global score was computed if at least the scores of 6 items were available. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 40, 52, and 64
Change From Baseline in BioSecure Questionnaire Score at Week 24
The BioSecure questionnaire comprised of 54-item aimed at evaluating the safety competences of participants (for example, participants' self-care safety skills and socio-demographic characteristics, type of information received, quality of life, and coping style data) treated by biologics for inflammatory arthritis and to determine the factors associated with a lower level of competences.
Time frame: Baseline, Week 24
Percentage of Participants With Discontinuations of Corticosteroid Dosage During Core Study Period
Percentage of participants with a discontinuation in corticosteroid dosage during core study period is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Time to Permanent Discontinuation of Corticosteroid Dosage During Core Study Period
Time to permanent discontinuation in corticosteroid dosage during core study period is reported. Participants who permanently discontinued corticosteroids at any time during core study period were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Time to First Temporary Discontinuation of Corticosteroid Dosage During Core Study Period
Time to first temporary discontinuation in corticosteroid dosage during core study period is reported. Participants who temporarily discontinued corticosteroids at any time during core study period were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Percentage of Participants With Change in Corticosteroid Dosage During Core Study Period
Percentage of participants with a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage.
Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Time to Change in Corticosteroid Dosage During Core Study Period
Time to first change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during core study period were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Number of Participants According to Reasons for Change in Corticosteroid Dosage During Core Study Period
Number of participants according to reasons for a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during core study period were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Percentage of Participants With Discontinuations of Corticosteroid Dosage During Study
Percentage of participants with a discontinuation in corticosteroid dosage during study is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)
Time to Permanent Discontinuation of Corticosteroid Dosage During Study
Time to permanent discontinuation in corticosteroid dosage during study is reported. Participants who permanently discontinued corticosteroids at any time during entire study were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)
Time to First Temporary Discontinuation of Corticosteroid Dosage During Study
Time to first temporary discontinuation in corticosteroid dosage during study is reported. Participants who temporarily discontinued corticosteroids at any time during entire study were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)
Percentage of Participants With Change in Corticosteroid Dosage During Study
Percentage of participants with a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage.
Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)
Time to Change in Corticosteroid Dosage During Study
Time to first change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during entire study were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)
Number of Participants According to Reasons for Change in Corticosteroid Dosage During Study
Number of participants according to reasons for a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during entire study were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)
Number of Participants According to Reasons for Changes in csDMARDs Treatment During Core Study Period
Number of participants according to reasons for changes in csDMARDs treatment during core study period is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to intravenous (IV)/ intramuscular (IM)/ SC. Participants with a change in csDMARDs treatment during core study period were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Number of Participants According to Reasons for Changes in csDMARDs Treatment During Study
Number of participants according to reasons for changes in csDMARDs treatment during study is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to IV/IM/SC. Participants with a change in csDMARDs treatment during entire study were only included in the analysis.
Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)
Change From Baseline in Synovitis Ultrasound B-Mode Score at Week 24
Synovitis was assessed by ultrasonographic evaluation (B-mode ultrasound) and scored from "0" to "3" for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal \[MCP 2/3\] on both sides, 2nd and 3rd proximal inter-phalangeal \[PIP 2/3\] on both sides, 2nd and 5th metatarsophalangeal \[MTP 2/5\] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
Time frame: Baseline, Weeks 24
Change From Baseline in Synovitis Ultrasound Power-Doppler Mode Score at Week 24
Synovitis was assessed by ultrasonographic evaluation (Power-Doppler-mode ultrasound) and scored from "0" to "3" for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal \[MCP 2/3\] on both sides, 2nd and 3rd proximal inter-phalangeal \[PIP 2/3\] on both sides, 2nd and 5th metatarsophalangeal \[MTP 2/5\] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
Time frame: Baseline, Weeks 24
Percentage of Participants With Anti-Therapeutic Antibodies to Tocilizumab
Percentage of participants with a positive response to anti-therapeutic antibodies against tocilizumab by confirmatory assays at any time during the study is reported.
Time frame: Baseline up to 8 weeks after last study drug administration (up to Week 84)
A total of 183 participants were screened; 139 participants were eligible for the study and assigned to study treatment.
| Milestone | TCZ - All Participants |
|---|---|
| Started | 139 |
| Completed | 116 |
| Not completed | 23 |
| Withdrew: Adverse event | 9 |
| Withdrew: Death | 1 |
| Withdrew: Non-serious hypersensitivity reaction | 2 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Lack of efficacy | 3 |
| Milestone | TCZ - All Participants |
|---|---|
| Started | 116 |
| Completed | 107 |
| Not completed | 9 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Physician decision | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Other | 3 |
The DAS28-ESR was derived from assessments of erythrocyte sedimentation rate (ESR), tender joint count (TJC), swollen joint count (SJC), and Patient Global Assessment of disease activity (PGA) according to 100-millimeter (mm) Visual Analog Scale (VAS). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in millimeters per hour (mm/h). DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to Week 24 was averaged among all participants, where negative changes indicated an improvement in disease activity.
| units on a scale | TCZ - All Participants - Core Study Period |
|---|---|
| Baseline | 5.80 ± 1.14 |
| Change at Week 24 | -3.07 ± 1.52 |
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
| units on a scale | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Baseline | 6.08 ± 1.21 | 5.67 ± 1.10 |
| Change at Week 2 | -1.19 ± 1.05 | -1.41 ± 1.03 |
| Change at Week 4 | -2.16 ± 1.17 | -2.21 ± 1.14 |
| Change at Week 8 | -2.70 ± 1.40 | -2.74 ± 1.36 |
| Change at Week 12 | -3.16 ± 1.54 | -3.02 ± 1.33 |
| Change at Week 16 | -3.20 ± 1.59 | -3.08 ± 1.29 |
| Change at Week 20 | -3.27 ± 1.35 | -3.21 ± 1.43 |
| Change at Week 24 | -3.01 ± 1.62 | -3.10 ± 1.48 |
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score less than or equal to (\</=) 3.2 indicates LDA, DAS28-ESR score greater than (\>) 3.2 indicates moderate to high disease activity, and DAS28-ESR less than (\<) 2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 is reported. 95 percent (%) confidence interval (CI) was determined using Clopper-Pearson method.
| percentage of participants | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| LDA | 67.4 (51.46 to 80.92) | 70.8 (60.67 to 79.67) |
| Remission | 41.9 (27.01 to 57.87) | 55.2 (44.71 to 65.37) |
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-millimeter (mm) VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline | 5.90 ± 1.26 |
| Change at Week 24 | -3.30 ± 1.44 |
| Change at Last Assessment | -3.41 ± 1.47 |
The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score \</=3.2 indicates LDA, DAS28-ESR score \>3.2 indicates moderate to high disease activity, and DAS28-ESR \<2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 and at last assessment is reported.
| percentage of participants | TCZ - All Participants |
|---|---|
| Week 24, LDA | 71.9 |
| Week 24, Remission | 54.7 |
| Last Assessment, LDA | 71.9 |
| Last Assessment, Remission | 53.1 |
The ACR 20, 50, and 70 responses at any time was defined as greater than or equal to (\>/=) 20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via a Health Assessment Questionnaire-Disability Index (HAQ-DI), and 5) Acute phase reactant (ESR in mm/h or C-Reactive Protein \[CRP\] in milligrams per liter \[mg/L\]). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.
| percentage of participants | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| ACR20 | 69.7 (51.29 to 84.41) | 73.8 (63.07 to 82.80) |
| ACR50 | 54.5 (36.35 to 71.89) | 52.4 (41.19 to 63.40) |
| ACR70 | 33.3 (17.96 to 51.83) | 28.6 (19.24 to 39.47) |
The ACR 20, 50, and 70 responses at any time is defined as \>/=20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/L). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 and at last assessment is reported.
| percentage of participants | TCZ - All Participants |
|---|---|
| Week 24, ACR20 | 76.6 |
| Week 24, ACR50 | 51.6 |
| Week 24, ACR70 | 35.9 |
| Last Assessment, ACR20 | 76.6 |
| Last Assessment, ACR50 | 56.3 |
| Last Assessment, ACR70 | 37.5 |
The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline \>1.2 with DAS28-ESR score \</=3.2; Moderate Response: change from baseline \>1.2 with DAS28-ESR score \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28-ESR score \</=5.1; No Response: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28-ESR score \>5.1. Percentage of participants with EULAR responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.
| percentage of participants | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Good Response | 58.1 (42.13 to 72.99) | 60.4 (49.92 to 70.25) |
| Moderate Response | 14.0 (5.30 to 27.93) | 19.8 (12.36 to 29.17) |
| No Response | 27.9 (15.33 to 43.67) | 19.8 (12.36 to 29.17) |
The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline \>1.2 with DAS28-ESR score \</=3.2; Moderate Response: change from baseline \>1.2 with DAS28-ESR score \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28-ESR score \</=5.1; No Response: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28-ESR score \>5.1. Percentage of participants with EULAR responses at Week 24 and at last assessment is reported.
| percentage of participants | TCZ - All Participants |
|---|---|
| Week 24, Good Response | 68.8 |
| Week 24, Moderate Response | 26.6 |
| Week 24, No Response | 4.7 |
| Last Assessment, Good Response | 65.6 |
| Last Assessment, Moderate Response | 31.3 |
| Last Assessment, No Response | 3.1 |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg per deciliter (dL). Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
| units on a scale | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Baseline | 35.42 ± 12.61 | 31.47 ± 11.77 |
| Change at Week 2 | -8.54 ± 10.67 | -9.20 ± 9.37 |
| Change at Week 4 | -14.23 ± 10.76 | -14.62 ± 11.33 |
| Change at Week 8 | -20.20 ± 13.22 | -17.47 ± 12.47 |
| Change at Week 12 | -23.09 ± 13.82 | -20.33 ± 12.97 |
| Change at Week 16 | -24.31 ± 15.14 | -21.39 ± 12.66 |
| Change at Week 20 | -24.41 ± 15.28 | -21.93 ± 13.35 |
| Change at Week 24 | -22.45 ± 14.48 | -20.31 ± 13.34 |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.
| percentage of participants | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| LDA | 46.5 (31.18 to 62.35) | 59.4 (48.87 to 69.29) |
| Remission | 18.6 (8.39 to 33.40) | 19.8 (12.36 to 29.17) |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
| units on a scale | TCZ - All Participants |
|---|---|
| Change at Week 24 | -23.29 ± 13.81 |
| Change at Last Assessment | -24.36 ± 12.61 |
SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 and at last assessment is reported.
| percentage of participants | TCZ - All Participants |
|---|---|
| Week 24, LDA | 57.8 |
| Week 24, Remission | 20.3 |
| Last Assessment, LDA | 64.1 |
| Last Assessment, Remission | 25.0 |
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
| units on a scale | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Baseline | 32.17 ± 11.11 | 29.34 ± 11.05 |
| Change at Week 2 | -5.57 ± 9.69 | -7.15 ± 8.87 |
| Change at Week 4 | -11.17 ± 10.14 | -12.65 ± 10.97 |
| Change at Week 8 | -17.32 ± 12.00 | -15.75 ± 11.62 |
| Change at Week 12 | -20.25 ± 12.50 | -18.17 ± 12.20 |
| Change at Week 16 | -20.24 ± 14.13 | -19.25 ± 11.88 |
| Change at Week 20 | -21.27 ± 13.58 | -19.29 ± 12.82 |
| Change at Week 24 | -19.45 ± 13.34 | -18.40 ± 12.78 |
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.
| percentage of participants | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| LDA | 44.2 (29.08 to 60.12) | 60.4 (49.92 to 70.25) |
| Remission | 16.3 (6.81 to 30.70) | 16.7 (9.84 to 25.65) |
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
| units on a scale | TCZ - All Participants |
|---|---|
| Change at Week 24 | -20.85 ± 13.06 |
| Change at Last Assessment | -21.74 ± 12.06 |
CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 and at last assessment is reported.
| percentage of participants | TCZ - All Participants |
|---|---|
| Week 24, LDA | 57.8 |
| Week 24, Remission | 17.2 |
| Last Assessment, LDA | 60.9 |
| Last Assessment, Remission | 23.4 |
A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
| swollen joints | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Baseline | 6.0 (0.0 to 24.0) | 7.0 (0.0 to 23.0) |
| Change at Week 2 | -1.0 (-9.0 to 14.0) | -2.0 (-13.0 to 8.0) |
| Change at Week 4 | -3.0 (-8.0 to 4.0) | -3.0 (-18.0 to 5.0) |
| Change at Week 8 | -3.5 (-18.0 to 6.0) | -4.0 (-17.0 to 3.0) |
| Change at Week 12 | -4.0 (-22.0 to 3.0) | -5.0 (-23.0 to 2.0) |
| Change at Week 16 | -5.0 (-22.0 to 6.0) | -5.0 (-23.0 to 2.0) |
| Change at Week 20 | -4.0 (-21.0 to 3.0) | -5.0 (-22.0 to 4.0) |
| Change at Week 24 | -5.0 (-21.0 to 14.0) | -5.0 (-23.0 to 2.0) |
A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.
| swollen joints | TCZ - All Participants |
|---|---|
| Change at Week 24 | -6.0 (-23.0 to 2.0) |
| Change at Last Assessment | -6.5 (-22.0 to 5.0) |
A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity.
| tender joints | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Baseline | 12.0 (0.0 to 28.0) | 8.0 (0.0 to 27.0) |
| Change at Week 2 | -1.0 (-13.0 to 12.0) | -2.0 (-18.0 to 12.0) |
| Change at Week 4 | -2.5 (-17.0 to 4.0) | -3.0 (-20.0 to 10.0) |
| Change at Week 8 | -6.5 (-19.0 to 12.0) | -5.0 (-21.0 to 8.0) |
| Change at Week 12 | -8.0 (-23.0 to 3.0) | -5.0 (-20.0 to 17.0) |
| Change at Week 16 | -8.0 (-24.0 to 8.0) | -5.5 (-23.0 to 4.0) |
| Change at Week 20 | -8.0 (-27.0 to 5.0) | -5.0 (-25.0 to 12.0) |
| Change at Week 24 | -8.0 (-27.0 to 12.0) | -5.0 (-27.0 to 15.0) |
A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity.
| tender joints | TCZ - All Participants |
|---|---|
| Change at Week 24 | -6.5 (-27.0 to 15.0) |
| Change at Last Assessment | -6.0 (-27.0 to 9.0) |
Physician-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in physician-assessed disease activity.
| mm | TCZ - All Participants |
|---|---|
| Baseline | 62.08 ± 17.68 |
| Change at Week 2 | -11.38 ± 15.91 |
| Change at Week 4 | -22.10 ± 20.25 |
| Change at Week 8 | -29.67 ± 23.33 |
| Change at Week 12 | -35.25 ± 22.03 |
| Change at Week 16 | -35.69 ± 23.33 |
| Change at Week 20 | -37.80 ± 21.80 |
| Change at Week 24 | -34.98 ± 22.43 |
Participant-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed disease activity.
| mm | TCZ - All Participants |
|---|---|
| Baseline | 59.88 ± 24.14 |
| Change at Week 2 | -8.11 ± 21.64 |
| Change at Week 4 | -17.19 ± 25.71 |
| Change at Week 8 | -24.49 ± 29.94 |
| Change at Week 12 | -29.62 ± 29.84 |
| Change at Week 16 | -31.61 ± 28.89 |
| Change at Week 20 | -31.80 ± 31.16 |
| Change at Week 24 | -33.79 ± 31.19 |
| Change at Week 28 | -37.90 ± 29.87 |
| Change at Week 32 | -33.96 ± 32.19 |
| Change at Week 36 | -34.10 ± 30.05 |
| Change at Week 40 | -37.74 ± 28.63 |
| Change at Week 44 | -36.55 ± 26.27 |
| Change at Week 48 | -37.63 ± 26.07 |
| Change at Week 52 | -37.50 ± 33.25 |
| Change at Week 56 | -41.00 ± 41.91 |
| Change at Week 60 | -46.00 ± 49.50 |
| Change at Week 64 | -42.50 ± 53.03 |
Participant-assessed pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of pain (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed pain.
| mm | TCZ - All Participants |
|---|---|
| Baseline | 57.57 ± 26.78 |
| Change at Week 2 | -7.50 ± 22.78 |
| Change at Week 4 | -15.28 ± 29.76 |
| Change at Week 8 | -22.58 ± 32.15 |
| Change at Week 12 | -28.29 ± 32.04 |
| Change at Week 16 | -29.50 ± 29.98 |
| Change at Week 20 | -30.55 ± 29.98 |
| Change at Week 24 | -31.85 ± 30.21 |
| Change at Week 28 | -33.29 ± 31.84 |
| Change at Week 32 | -32.67 ± 30.98 |
| Change at Week 36 | -34.51 ± 30.03 |
| Change at Week 40 | -34.36 ± 31.07 |
| Change at Week 44 | -32.30 ± 27.10 |
| Change at Week 48 | -35.56 ± 26.27 |
| Change at Week 52 | -36.42 ± 32.77 |
| Change at Week 56 | -39.50 ± 34.67 |
| Change at Week 60 | -42.00 ± 43.84 |
| Change at Week 64 | -40.00 ± 43.84 |
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated questions), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). The changes from Baseline to any time point were averaged among all participants, where negative changes indicated an increase in fatigue.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline | 25.44 ± 11.97 |
| Change at Week 2 | 3.71 ± 8.20 |
| Change at Week 4 | 6.08 ± 9.74 |
| Change at Week 8 | 7.98 ± 12.36 |
| Change at Week 12 | 9.43 ± 11.54 |
| Change at Week 16 | 9.19 ± 11.89 |
| Change at Week 20 | 8.84 ± 12.68 |
| Change at Week 24 | 9.26 ± 13.08 |
| Change at Week 28 | 11.54 ± 12.18 |
| Change at Week 32 | 9.87 ± 12.25 |
| Change at Week 36 | 8.63 ± 12.17 |
| Change at Week 40 | 10.41 ± 11.73 |
| Change at Week 44 | 10.30 ± 12.37 |
| Change at Week 48 | 11.50 ± 9.14 |
| Change at Week 52 | 12.25 ± 10.70 |
| Change at Week 56 | 14.83 ± 7.36 |
| Change at Week 60 | 17.00 ± 7.07 |
| Change at Week 64 | 20.00 ± 7.07 |
HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI remission (HAQ-DI score \<0.5) at each time point is reported.
| percentage of participants | TCZ - All Participants |
|---|---|
| Baseline | 6.0 |
| Week 2 | 8.4 |
| Week 4 | 12.6 |
| Week 8 | 23.3 |
| Week 12 | 31.7 |
| Week 16 | 35.9 |
| Week 20 | 31.3 |
| Week 24 | 30.3 |
| Week 28 | 37.3 |
| Week 32 | 32.1 |
| Week 36 | 25.0 |
| Week 40 | 30.4 |
| Week 44 | 30.0 |
| Week 48 | 25.0 |
| Week 52 | 33.3 |
| Week 56 | 33.3 |
| Week 60 | 50.0 |
| Week 64 | 50.0 |
HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI clinically meaningful improvement (reduction in HAQ-DI score from baseline \>/=0.22) at each time point is reported.
| percentage of participants | TCZ - All Participants |
|---|---|
| Week 2 | 42.5 |
| Week 4 | 55.3 |
| Week 8 | 62.1 |
| Week 12 | 71.6 |
| Week 16 | 75.0 |
| Week 20 | 67.6 |
| Week 24 | 73.6 |
| Week 28 | 76.8 |
| Week 32 | 72.0 |
| Week 36 | 64.9 |
| Week 40 | 73.9 |
| Week 44 | 65.0 |
| Week 48 | 62.5 |
| Week 52 | 50.0 |
| Week 56 | 66.7 |
| Week 60 | 100.0 |
| Week 64 | 50.0 |
Treatment compliance from Baseline up to Week 24 was assessed using following formula: (number of actual injection received / number of theoretical injection which should be received at week 24) \* 100.
| percentage of injections | TCZ - All Participants - Core Study Period |
|---|---|
| Treatment Compliance From Baseline up to Week 24 | 91.19 ± 15.54 |
RAID assessed the impact of rheumatoid arthritis on participant's quality of life. It comprised 7 domains: pain, function, fatigue, physical and psychological well-being, sleep disturbance and coping. Each domain was a single question scored from 0 (best) to 10 (worst) on a continuous numerical rating scale (NRS). Each domain also had a specific weight assigned by a participant survey and RAID total score ranged from 0 (best) to 10 (worst). If only 1 domain was missing it was replaced by the mean of the others; otherwise, RAID score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline | 5.94 ± 2.27 |
| Change at Week 12 | -2.74 ± 2.39 |
| Change at Week 24 | -2.94 ± 2.65 |
| Change at Week 28 | -2.99 ± 2.50 |
| Change at Week 40 | -3.21 ± 2.46 |
| Change at Week 52 | -3.27 ± 2.52 |
| Change at Week 64 | -5.59 ± 0.74 |
RAPID-3 is a combined index derived from the Multidimensional Health Assessment Questionnaire that includes physical function score, pain VAS, and PGA VAS. The total RAPID-3 score ranges from 0 to 10 where higher scores represent worse outcomes. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline | 15.41 ± 6.54 |
| Change at Week 2 | -1.72 ± 4.96 |
| Change at Week 4 | -4.18 ± 6.08 |
| Change at Week 12 | -7.07 ± 7.01 |
| Change at Week 24 | -7.68 ± 7.16 |
| Change at Week 28 | -8.16 ± 6.81 |
| Change at Week 40 | -8.86 ± 6.70 |
| Change at Week 52 | -8.91 ± 7.79 |
| Change at Week 64 | -9.00 ± 9.90 |
Participants were asked: "If you were to remain in the same condition for the next few months as you have been over the last 8 days, would this be 1) acceptable, 2) Inacceptable?" The number of participants who responded "acceptable" or "Inacceptable" at each time point is presented.
| Participants | TCZ - All Participants |
|---|---|
| Baseline, Acceptable | 31 |
| Baseline, Inacceptable | 101 |
| Week 24, Acceptable | 78 |
| Week 24, Incceptable | 27 |
| Week 52, Acceptable | 8 |
| Week 52, Inacceptable | 3 |
| Last Assessment, Acceptable | 83 |
| Last Assessment, Inacceptable | 35 |
BRAF-MDQ assessed the overall experience and impact of disease related fatigue, using four dimensions (physical fatigue \[4 items\], living with fatigue \[7 items\], cognitive fatigue \[5 items\], and emotional fatigue \[4 items\]). A total fatigue score (range 0 to 70) was obtained by summing the 20 item scores ranging from 0 to 3, except for item 1 (0-10), item 2 (0-7) and item 3 (0-2). Higher scores reflect greater fatigue. If only 1 domain was missing it was replaced by the mean of the others; otherwise, the total score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline | 35.50 ± 18.93 |
| Change at Week 24 | -13.18 ± 18.56 |
| Change at Week 52 | -20.09 ± 19.02 |
BRAF-NRS are 3 standardized NRS (range = 0-10) for disease related fatigue domains (severity of fatigue, fatigue effect, and coping with fatigue). Higher values reflect greater problems for severity/level fatigue and effect fatigue NRS, but lower scores reflect greater problems for copped fatigue NRS.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline, Level Fatigue NRS | 6.14 ± 2.56 |
| Baseline, Effect Fatigue NRS | 5.87 ± 2.75 |
| Baseline, Copped Fatigue NRS | 5.48 ± 2.52 |
| Change at Week 24, Level Fatigue NRS | -2.41 ± 2.90 |
| Change at Week 24, Effect Fatigue NRS | -2.44 ± 2.90 |
| Change at Week 24, Copped Fatigue NRS | -0.47 ± 3.91 |
| Change at Week 52, Level Fatigue NRS | -3.75 ± 2.93 |
| Change at Week 52, Effect Fatigue NRS | -3.83 ± 2.86 |
| Change at Week 52, Copped Fatigue NRS | -1.33 ± 2.84 |
MOS sleep scale comprised of 6-item with each item score ranged from 0 to 100. The total score was the average of scores sum (range 0-100), with highest values reflecting biggest participant's sleeping problems. If more than 3 items were missing the index was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline | 47.09 ± 21.66 |
| Change at Week 12 | -7.21 ± 18.85 |
| Change at Week 24 | -5.44 ± 19.83 |
| Change at Week 28 | -8.48 ± 15.04 |
| Change at Week 40 | -5.56 ± 14.45 |
| Change at Week 52 | -8.33 ± 18.11 |
| Change at Week 64 | -27.08 ± 2.95 |
FLARE is a 13-item questionnaire assessed disease flares between two medical consultations. Each item score ranged from 0 (completely untrue) to 10 (absolutely true) on a 6-step scale. The FLARE questionnaire global score (range = 0-10) is a mean score of 11 of the 13 items \[items 6 ('doses of pain killers or anti-inflammatory medication') and 13 ('need for help') not taken into account\], with the highest score corresponding to the highest disease activity. The global score was computed if at least the scores of 6 items were available. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline | 5.61 ± 2.77 |
| Change at Week 2 | -1.35 ± 2.41 |
| Change at Week 4 | -2.38 ± 2.64 |
| Change at Week 8 | -2.94 ± 3.18 |
| Change at Week 12 | -3.41 ± 2.62 |
| Change at Week 16 | -3.10 ± 2.89 |
| Change at Week 20 | -3.30 ± 2.93 |
| Change at Week 24 | -3.41 ± 2.75 |
| Change at Week 28 | -3.31 ± 2.54 |
| Change at Week 40 | -3.44 ± 2.01 |
| Change at Week 52 | -4.16 ± 1.99 |
| Change at Week 64 | -7.55 ± 1.54 |
The BioSecure questionnaire comprised of 54-item aimed at evaluating the safety competences of participants (for example, participants' self-care safety skills and socio-demographic characteristics, type of information received, quality of life, and coping style data) treated by biologics for inflammatory arthritis and to determine the factors associated with a lower level of competences.
No measurements were reported for this outcome.
Percentage of participants with a discontinuation in corticosteroid dosage during core study period is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis.
| percentage of participants | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Permanent Discontinuation | 8.3 | 7.3 |
| Temporary Discontinuation | 16.7 | 7.3 |
Time to permanent discontinuation in corticosteroid dosage during core study period is reported. Participants who permanently discontinued corticosteroids at any time during core study period were only included in the analysis.
| days | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Time to Permanent Discontinuation of Corticosteroid Dosage During Core Study Period | 24 (1 to 46) | 96 (24 to 114) |
Time to first temporary discontinuation in corticosteroid dosage during core study period is reported. Participants who temporarily discontinued corticosteroids at any time during core study period were only included in the analysis.
| days | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Time to First Temporary Discontinuation of Corticosteroid Dosage During Core Study Period | 50 (1 to 156) | 105 (76 to 138) |
Percentage of participants with a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage.
| percentage of participants | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Initiation/ Increase | 0.0 | 3.1 |
| Decrease | 14.0 | 9.4 |
Time to first change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during core study period were only included in the analysis.
| days | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Initiation/ Increase | — | 38 (23 to 50) |
| Decrease | 98 (1 to 239) | 107 (25 to 225) |
Number of participants according to reasons for a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during core study period were only included in the analysis.
| Participants | TCZ MONO - Core Study Period | TCZ COMBO - Core Study Period |
|---|---|---|
| Initiation/ Increase, Lack of Efficacy | 0 | 1 |
| Initiation/ Increase, End of Treatment Planned | 0 | 1 |
| Initiation/ Increase, Other Reason | 0 | 1 |
| Decrease, Adverse Event | 1 | 0 |
| Decrease, Lack of Efficacy | 0 | 1 |
| Decrease, End of Treatment Planned | 2 | 3 |
| Decrease, Other Reason | 3 | 5 |
Percentage of participants with a discontinuation in corticosteroid dosage during study is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis.
| percentage of participants | TCZ - All Participants |
|---|---|
| Permanent Discontinuation | 10.0 |
| Temporary Discontinuation | 15.0 |
Time to permanent discontinuation in corticosteroid dosage during study is reported. Participants who permanently discontinued corticosteroids at any time during entire study were only included in the analysis.
| days | TCZ - All Participants |
|---|---|
| Time to Permanent Discontinuation of Corticosteroid Dosage During Study | 202 (107 to 328) |
Time to first temporary discontinuation in corticosteroid dosage during study is reported. Participants who temporarily discontinued corticosteroids at any time during entire study were only included in the analysis.
| days | TCZ - All Participants |
|---|---|
| Time to First Temporary Discontinuation of Corticosteroid Dosage During Study | 147 (96 to 290) |
Percentage of participants with a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage.
| percentage of participants | TCZ - All Participants |
|---|---|
| Initiation/ Increase | 3.1 |
| Decrease | 21.9 |
Time to first change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during entire study were only included in the analysis.
| days | TCZ - All Participants |
|---|---|
| Initiation/ Increase | 44 (38 to 50) |
| Decrease | 210 (96 to 428) |
Number of participants according to reasons for a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during entire study were only included in the analysis.
| Participants | TCZ - All Participants |
|---|---|
| Initiation/ Increase, Lack of Efficacy | 1 |
| Initiation/ Increase, Other Reason | 1 |
| Decrease, Lack of Efficacy | 1 |
| Decrease, End of Treatment Planned | 4 |
| Decrease, Other Reason | 9 |
Number of participants according to reasons for changes in csDMARDs treatment during core study period is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to intravenous (IV)/ intramuscular (IM)/ SC. Participants with a change in csDMARDs treatment during core study period were only included in the analysis.
| Participants | TCZ - All Participants - Core Study Period |
|---|---|
| Adverse Event | 19 |
| End of Treatment Planned | 2 |
| Lack of Efficacy | 1 |
| Poor Treatment Compliance | 1 |
| Other Reason | 6 |
Number of participants according to reasons for changes in csDMARDs treatment during study is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to IV/IM/SC. Participants with a change in csDMARDs treatment during entire study were only included in the analysis.
| Participants | TCZ - All Participants |
|---|---|
| Adverse Event | 5 |
| End of Treatment Planned | 1 |
| Lack of Efficacy | 2 |
| Poor Treatment Compliance | 1 |
| Other Reason | 3 |
Synovitis was assessed by ultrasonographic evaluation (B-mode ultrasound) and scored from "0" to "3" for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal \[MCP 2/3\] on both sides, 2nd and 3rd proximal inter-phalangeal \[PIP 2/3\] on both sides, 2nd and 5th metatarsophalangeal \[MTP 2/5\] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline | 14.0 (2.0 to 37.0) |
| Change at Week 24 | -8.0 (-29.0 to 8.0) |
Synovitis was assessed by ultrasonographic evaluation (Power-Doppler-mode ultrasound) and scored from "0" to "3" for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal \[MCP 2/3\] on both sides, 2nd and 3rd proximal inter-phalangeal \[PIP 2/3\] on both sides, 2nd and 5th metatarsophalangeal \[MTP 2/5\] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.
| units on a scale | TCZ - All Participants |
|---|---|
| Baseline | 5.0 (0.0 to 26.0) |
| Change at Week 24 | -4.0 (-21.0 to 11.0) |
Percentage of participants with a positive response to anti-therapeutic antibodies against tocilizumab by confirmatory assays at any time during the study is reported.
| percentage of participants | TCZ - All Participants |
|---|---|
| Percentage of Participants With Anti-Therapeutic Antibodies to Tocilizumab | 3.6 |
Collected over Baseline up to 8 weeks after last study drug administration (up to Week 84). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TCZ MONO - All Participants | — | 5/43 (11.6%) | 28/43 (65.1%) |
| TCZ COMBO - All Participants | — | 11/96 (11.5%) | 65/96 (67.7%) |
| TCZ - All Participants | — | 16/139 (11.5%) | 93/139 (66.9%) |
| Event | TCZ MONO - All Participants | TCZ COMBO - All Participants | TCZ - All Participants |
|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/43 | 1/96 | 3/139 |
| Abdominal painGastrointestinal disorders | 1/43 | 0/96 | 1/139 |
| DiarrhoeaGastrointestinal disorders | 1/43 | 0/96 | 1/139 |
| DyspepsiaGastrointestinal disorders | 1/43 | 0/96 | 1/139 |
| VomitingGastrointestinal disorders | 1/43 | 0/96 | 1/139 |
| Lung disorderRespiratory, thoracic and mediastinal disorders | 1/43 | 0/96 | 1/139 |
| Myocardial infarctionCardiac disorders | 1/43 | 0/96 | 1/139 |
| NephrolithiasisRenal and urinary disorders | 1/43 | 0/96 | 1/139 |
| Gastric ulcerGastrointestinal disorders | 0/43 | 1/96 | 1/139 |
| Gastric volvulusGastrointestinal disorders | 0/43 | 1/96 | 1/139 |
| Event | TCZ MONO - All Participants | TCZ COMBO - All Participants | TCZ - All Participants |
|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 8/43 | 11/96 | 19/139 |
| BronchitisInfections and infestations | 7/43 | 9/96 | 16/139 |
| Ear infectionInfections and infestations | 5/43 | 3/96 | 8/139 |
| RhinitisInfections and infestations | 2/43 | 11/96 | 13/139 |
| AstheniaGeneral disorders | 1/43 | 9/96 | 10/139 |
| NasopharyngitisInfections and infestations | 4/43 | 8/96 | 12/139 |
| Urinary tract infectionInfections and infestations | 4/43 | 4/96 | 8/139 |
| Back painMusculoskeletal and connective tissue disorders | 4/43 | 5/96 | 9/139 |
| NauseaGastrointestinal disorders | 4/43 | 2/96 | 6/139 |
| Injection site erythemaGeneral disorders | 4/43 | 3/96 | 7/139 |
Full Analysis Set (FAS) included all participants who received at least one dose of SC TCZ.
| Age, Continuous(years) | TCZ - All Participants |
|---|---|
| Mean | 57.3 ± 13.8 |
| Sex: Female, Male(Participants) | TCZ - All Participants |
|---|---|
| Female | 103 |
| Male | 36 |
The record gives a start of Jan 2014, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab